Community acquired pneumonia (CAP), together with lower respiratory tract infections, is the fourth most common cause of death globally, mostly affecting the elderly and children under 5 years of age. Timely diagnosis of the condition, identification of its cause and selection of the treatment is fundamental to reduce loss of lives. However, current diagnostic methods are too slow and increasing antibiotic resistances make it harder to treat. As a result, the societal and economic costs caused by pneumonia cannot be mitigated
PneumoSIP is a novel solution for the problem of pneumonia, that helps doctors confirm, in less than 2 hours, the existence of the disease, identify what is causing it and provide information to better selector the treatment. Therefore, PneumoSIP provides the right information for doctors to take the best possible decisions: patients are treated faster and better and mortality is reduced. PneumoSIP also improves the efficiency of Europe’s healthcare system by allowing hospitals to do more work in less time and reducing the overall costs due to testing, hospitalization and incorrect treatment.
PneumoSIP’s main objective is to minimize loss of life due to pneumonia by providing a fast, accurate, affordable and fully automated solution. PneumoSIP can be used by a variety of healthcare professionals in most healthcare centres, thus being available for the whole society.
